tbuckley/cabot-search huggingface dataset:
Living symbiotic bacteria-involved skin dressing to combat indigenous pathogens for microbiome-based biotherapy toward atopic dermatitis
Authors: Xinhua Liu, Youteng Qin, Liyun Dong, Ziyi Han, Tianning Liu, Ying Tang, Yun Yu, Jingjie Ye, Juan Tao, Xuan Zeng, Jun Feng, Xian-Zheng Zhang
Journal: Bioactive Materials (2022)

Many skin diseases, such as atopic dermatitis (AD), are featured with the dysbiosis of skin microbiota. The clinically recommended options for AD treatments suffer from poor outcomes and high side-effects, leading to severe quality-of-life impairment. To deal with this long-term challenge, we develop a living bacterial formulation (Hy@Rm) that integrates skin symbiotic bacteria of Roseomonas mucosa with poly(vinyl pyrrolidone), poly(vinyl alcohol) and sodium alginate into a skin dressing by virtue of the Ca2+-mediated cross-linking and the freezing-thawing (F-T) cycle method. Hy@Rm dressing creates a favorable condition to not only serve as extrinsic culture harbors but also as nutrient suppliers to support R. mucosa survival in the harsh microenvironment of AD sites to defeat S. aureus, which predominantly colonizes AD skins as an indigenous pathogen, mainly through the secretion of sphingolipids metabolites by R. mucosa like a therapeutics bio-factory. Meanwhile, this elaborately designed skin dressing could accelerate wound healing, normalize aberrant skin characters, recover skin barrier functions, alleviate AD-associated immune/inflammation responses, functioning like a combinational therapy. This study offers a promising means for the topical bacteria transplant to realize effective microbe biotherapy toward the skin diseases feature with microbe milieu disorders, including but not limited to AD disease.
Injectable nanofiber-reinforced bone cement with controlled biodegradability for minimally-invasive bone regeneration
Authors: Peihao Cai, Shunyi Lu, Jieqin Yu, Lan Xiao, Jiayi Wang, Haifeng Liang, Lei Huang, Guanjie Han, Mengxuan Bian, Shihao Zhang, Jian Zhang, Changsheng Liu, Libo Jiang, Yulin Li
Journal: Bioactive Materials (2022)

Injectable materials show their special merits in regeneration of damaged/degenerated bones in minimally-invasive approach. Injectable calcium phosphate bone cement (CPC) has attracted broad attention for its bioactivity, as compared to non-degradable polymethyl methacrylate cement. However, its brittleness, poor anti-washout property and uncontrollable biodegradability are the main challenges to limit its further clinical application mainly because of its stone-like dense structure and fragile inorganic-salt weakness. Herein, we developed a kind of injectable CPC bone cement with porous structure and improved robustness by incorporating poly(lactide-co-glycolic acid) (PLGA) nanofiber into CPC, with carboxymethyl cellulose (CMC) to offer good injectability as well as anti-wash-out capacity. Furthermore, the introduction of PLGA and CMC also enabled a formation of initial porous structure in the cements, where PLGA nanofiber endowed the cement with a dynamically controllable biodegradability which provided room for cell movement and bone ingrowth. Interestingly, the reinforced biodegradable cement afforded a sustainable provision of Ca2+ bioactive components, together with its porous structure, to improve synergistically new bone formation and osteo-integration in vivo by using a rat model of femur condyle defect. Further study on regenerative mechanisms indicated that the good minimally-invasive bone regeneration may come from the synergistic enhanced osteogenic effect of calcium ion enrichment and the improved revascularization capacity contributed from the porosity as well as the lactic acid released from PLGA nanofiber. These results indicate the injectable bone cement with high strength, anti-washout property and controllable biodegradability is a promising candidate for bone regeneration in a minimally-invasive approach.
Phase-change composite filled natural nanotubes in hydrogel promote wound healing under photothermally triggered drug release
Authors: Jing-Jing Ye, Long-Fei Li, Rui-Nan Hao, Min Gong, Tong Wang, Jian Song, Qing-Han Meng, Na-Na Zhao, Fu-Jian Xu, Yuri Lvov, Li-Qun Zhang, Jia-Jia Xue
Journal: Bioactive Materials (2022)

It is of great importance to treat a bacterial-infected wound by a smart dressing capable of delivering antibiotics in a smart manner without causing drug resistance. The construction of smart release nanocontainers responsive to near-infrared (NIR) laser irradiation in an on-demand and stepwise way is a promising strategy for avoiding the emergence of multidrug-resistant bacteria. Here, we develop a hydrogel composite made of alginate and nanotubes with an efficient NIR-triggered release of rifampicin and outstanding antibacterial ability. This composite hydrogel is prepared through co-encapsulating antibacterial drug (rifampicin), NIR-absorbing dye (indocyanine green), and phase-change materials (a eutectic mixture of fatty acids) into halloysite nanotubes, followed by incorporation into alginate hydrogels, allowing the in-situ gelation at room temperature and maintaining the integrity of drug-loaded nanotubes. Among them, the eutectic mixture with a melting point of 39 °C serves as the biocompatible phase-change material to facilitate the NIR-triggered drug release. The resultant phase-change material gated-nanotubes exhibit a prominent photothermal efficiency with multistep drug release under laser irradiation. In an in vitro assay, composite hydrogel provides good antibacterial potency against Staphylococcus aureus, one of the most prevalent microorganisms of dangerous gas gangrene. A bacterial-infected rat full-thickness wound model demonstrates that the NIR-responsive composite hydrogel inhibits the bacteria colonization and suppresses the inflammatory response caused by bacteria, promoting angiogenesis and collagen deposition to accelerate wound regeneration. The NIR-responsive composite hydrogel has a great potential as an antibacterial wound dressing functionalized with controlled multistep treatment of the infected sites.
Health-Related Quality of Life in Primary Care Patients With Mental Disorders
Authors: Robert L. Spitzer, Kurt Kroenke, Mark Linzer, Steven R. Hahn, Janet B. W. Williams, Frank Verloin deGruy, David Brody, Mark Davies
Journal: JAMA (1995)

<h3>Objective.</h3> —To determine if different mental disorders commonly seen in primary care are uniquely associated with distinctive patterns of impairment in the components of health-related quality of life (HRQL) and how this compares with the impairment seen in common medical disorders. <h3>Design.</h3> —Survey. <h3>Setting.</h3> —Four primary care clinics. <h3>Subjects.</h3> —A total of 1000 adult patients (369 selected by convenience and 631 selected by site-specific methods to avoid sampling bias) assessed by 31 primary care physicians using PRIME-MD (Primary Care Evaluation of Mental Disorders) to make diagnoses of mood, anxiety, alcohol, somatoform, and eating disorders. <h3>Main Outcome Measures.</h3> —The six scales of the Short-Form General Health Survey and self-reported disability days, adjusting for demographic variables as well as psychiatric and medical comorbidity. <h3>Results.</h3> —Mood, anxiety, somatoform, and eating disorders were associated with substantial impairment in HRQL. Impairment was also present in patients who only had subthreshold mental disorder diagnoses, such as minor depression and anxiety disorder not otherwise specified. Mental disorders, particularly mood disorders, accounted for considerably more of the impairment on all domains of HRQL than did common medical disorders. Finally, we found marked differences in the pattern of impairment among different groups of mental disorders just as others have reported unique patterns associated with different medical disorders. Whereas mood disorders had a pervasive effect on all domains of HRQL, anxiety, somatoform, and eating disorders affected only selected domains. <h3>Conclusions.</h3> —Mental disorders commonly seen in primary care are not only associated with more impairment in HRQL than common medical disorders, but also have distinct patterns of impairment. Primary care directed at improving HRQL needs to focus on the recognition and treatment of common mental disorders. Outcomes studies of mental disorders in both primary care and psychiatric settings should include multidimensional measures of HRQL. (<i>JAMA</i>. 1995;274:1511-1517)
1378P Biopsy-based basal-luminal subtyping classifier in high-risk prostate cancer: Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 randomized phase III trials
Authors: P. Nguyen, V. Liu, J.A. Proudfoot, E. Davicioni, Y. Liu, A. Dal Pra, D.E. Spratt, H.M. Sandler, J.A. Efstathiou, C. Lawton, J.P. Simko, S. Rosenthal, K. Zeitzer, L. Mendez, A. Hartford, W. Hall, A. Desai, S. Pugh, P.T. Tran, F. Feng
Journal: Annals of Oncology (2022)
1557MO Phase II trial evaluating effect of gonyautoxins (GTX), a paralytic shellfish poisoning (PSP) on objective and subjective symptoms of chemotherapy-induced peripheral neuropathy (CIPN)
Authors: M. Dias, L. Landeiro, R. Cunha Guimaraes, F. Copati, M. Mano, F. Souza Lima, C. Naurath, C. Sigala Orellana, F. Rondao, R. Dienstmann, J. Canedi, B. Ferrari, C.G. Ferreira
Journal: Annals of Oncology (2022)
1762P MERINOS: Metastatic non muscle invasive urothelial carcinoma - An observational study
Authors: M. Haberstich, G. Pignot, J. Rigaud, M. Cancel, D. Maillet, S. Oudard, D. Pouessel, C. Serrate, L. Campedel, C. Dumont, D. Borchiellini, P. Barthelemy, E. Boughalem, E. Colomba, O. Huillard, H.J. Boyle, F. Lefort, F. Constans Schlurmann, F. Audenet, C. Thibault
Journal: Annals of Oncology (2022)
1643TiP First-in-human dose-escalation and expansion study (MITOPE) to evaluate mitochondrial PRX3 inhibition by RSO-021 in patients with mesothelioma and other advanced solid tumors
Authors: S. Dulloo, D.A. Fennell, P.W. Szlosarek, F. Thistlethwaite, S. Lord, N.M. Rahman, A. Greystoke, B. Cunniff, J. Dzialo, C. Poile, R. Panchal, J. Duncan, P. Graham, A.S. Bexon, G. Naumov, J. Spicer
Journal: Annals of Oncology (2022)
1515P Nationwide management of soft tissue sarcoma (STS) in France, before (2019) versus during COVID-19 pandemic (2020)
Authors: N. Penel, A. Giraud, C. Chemin, C. Cantarel, F. Ducimetiere, C. Honoré, A. Le Cesne, F. Gouin, M. Toulmonde, G. Decanter, S. Bonvalot, C.M. Chevreau, P. Anract, N. Firmin, F. Duffaud, J.E. Kurtz, E. Bompas, M. Ropars, J-Y. Blay, S. Mathoulin-Pelissier
Journal: Annals of Oncology (2022)
1683P Implementing next generation sequencing (NGS)/molecular tumor board (MTB)-based precision oncology practice: One-year experience at the Verona University Hospital
Authors: S.T. Riva, C. Luchini, F. Zacchi, A. Mafficini, M. Borghesani, M. Mongillo, I.M. Scaglione, S. Manduca, E. Lucin, V. Moscarda, S. Pafumi, L.C. Leta, A. Dodi, A. Reni, L. Messineo, C. Chiamulera, E.D.L. Urso, A. Scarpa, R. Lawlor, M. Milella
Journal: Annals of Oncology (2022)
1375P Intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
Authors: S. Halabi, A. Roy, L. Rydzewska, P. Godolphin, M.K. Parmar, M. Hussain, C. Tangen, I.M. Thompson, W. Xie, M.A. Carducci, M. Smith, M.J. Morris, G. Gravis Mescam, D. Dearnaley, P. Verhagen, T. Goto, N.D. James, M.E. Buyse, J. Tierney, C.J. Sweeney
Journal: Annals of Oncology (2022)
1585P Thromboprophylaxis “challenge” in oncology patients with high burden for thrombosis: Real-world data from GMaT and ACT4CAT studies
Authors: N.G. Tsoukalas, A.N. Christopoulou, E. Timotheadou, A. Koumarianou, A. Ardavanis, I. Athanasiadis, M. Demiri, A. Bokas, G.F. Samelis, S. Peroukidis, G. Papatsimpas, C. Andreadis, A. Nikolakopoulos, A. Psyrri, N. Kapodistrias, P. Papakostas, G. Aravantinos, A. Athanasiadis, P. Papakotoulas, I. Boukovinas
Journal: Annals of Oncology (2022)
1697P Drug-induced evolutionary dynamics in BRCA-mutant/non-mutant ovarian cancer models
Authors: A.H. Ingles Russo Garces, S. Milite, E. Oliveira, J. Fernandez-Mateos, B. Chen, L. Pickard, A. Stewart, R. Lau, A. De Haven Brandon, E. Paranjape, A. Sottoriva, S. Banerjee, U. Banerji
Journal: Annals of Oncology (2022)
1666P Lower virus neutralizing titers against SARS-CoV-2 Omicron strain after third dose BNT162b2 following primo-vaccination with ChAdOx1 versus BNT162b2 in cancer patients
Authors: Y. Debie, J. Van Audenaerde, T. Vandamme, L. Croes, L-A.M.N. Teuwen, L. Verbruggen, G. Vanhoutte, E. Marcq, D. Le Blon, B. Peeters, None M.E. Goossens, K. Arien, S. Anguille, E. Smits, C. Vulsteke, E. Lion, M. Peeters, P.A. van Dam
Journal: Annals of Oncology (2022)
1713P Single-cell transcriptomic analysis of appendiceal cancer peritoneal disease
Authors: M.C. Strach, N. Yeung, E. Apostolov, H-M. Lin, R.T. Nagaraju, N. Ansari, C. Koh, J-S. Shin, J. Kench, O. Aziz, A. Swarbrick, L.G. Horvath, J. Barriuso, K. Mahon
Journal: Annals of Oncology (2022)
1510P Selective intra-arterial doxorubicin-eluting embolization for desmoid fibromatosis: A combined prospective and retrospective study
Authors: E. Elnekave, E. Ben Ami, S. Shamai, I. Peretz, J.P. Erinjeri, A. Stemmer, J. Ricke, M. Seidensticker, M. Wildgruber, S. Ash, A. Zer
Journal: Annals of Oncology (2022)
1760P Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Results from patients with ≥12 mo of treatment in JAVELIN Bladder 100
Authors: J.B. Aragon-Ching, P. Grivas, Y. Loriot, J. Bellmunt, J. Wang, E. Michelon, A. di Pietro, T.B. Powles, S. Sridhar
Journal: Annals of Oncology (2022)
1365P The impact of PSMA-positive circulating tumor cells in men with metastatic castrate-resistant prostate cancer (mCRPC)
Authors: S. Gupta, Q. Yang, S. Halabi, A. Tubbs, Y. Gore, D.J. George, D.M. Nanus, E.S. Antonarakis, D. Danila, R. Szmulewitz, R.J. Wenstrup, A.J. Armstrong
Journal: Annals of Oncology (2022)
1730P The variation of T cell receptor (TCR) diversity and genomic human leukocyte antigen-I (HLA-I) among non-small cell lung cancer (NSCLC) patients expressing high PDL1 versus those with low or no PDL1
Authors: A. Abed, A. Beasley, None C. Leslie, A. Reid, M. Millward, E.S. Gray
Journal: Annals of Oncology (2022)
1540P Real-world analysis of outcomes of first-line chemo-immunotherapy in patients with extensive disease small cell lung cancer (ED-SCLC)
Authors: N.M. Zellweger, S. Schmid, M. Bertschinger, C. Waibel, F.W.F. Cerciello, P.R. Froesch, M.T. Mark, A. Bettini, P. Häuptle, V. Blum, T. Litke, F. Helfenstein, M. Frueh, L.A. Mauti, S.I. Rothschild
Journal: Annals of Oncology (2022)
1763P Real-world outcomes before and after the access to immune-checkpoint inhibitors (ICI) in advanced urothelial carcinoma (aUC)
Authors: J.C. Tapia, G. Anguera Palacios, J. Gavira, F. Bosma, S. Sanchez Del Rio, J. Sanz Beltran, M.A. Molina Pérez, M. Aguado Sorolla, A. Piedra, J.P. Maroto Rey
Journal: Annals of Oncology (2022)
1385P Transcriptome-based prognostic and predictive biomarker analysis of ENACT: A randomized controlled trial of enzalutamide (ENZA) in men undergoing active surveillance (AS)
Authors: A. Ross, K.K. Iwata, D. Elsouda, J. Hairston, D. Russell, E. Davicioni, J.A. Proudfoot, N.D. Shore, M.R. Cooperberg, E.M. Schaeffer
Journal: Annals of Oncology (2022)
1754P Association between body mass index (BMI) and anti-PD1/L1 immune checkpoint inhibitor (ICI) outcomes in patients with metastatic urothelial carcinoma (mUC)
Authors: S. Labidi, None N. Meti, None R. Barua, J.J. Riromar, A.R. Hansen, D.M. Jiang, N. Fallah-Rad, S. Sridhar, C. Ferrario, R. Pezo, S. Cheng, A. Sacher, A. Rose
Journal: Annals of Oncology (2022)
442TiP A multicenter phase II clinical study evaluating the efficacy and safety of perioperative encorafenib, binimetinib plus cetuximab combination treatment in patients with surgically resectable BRAF V600E-mutant colorectal oligometastases (NEXUS)
Authors: S. Kobayashi, H. Bando, A. Taketomi, T. Takamoto, E. Shinozaki, M. Shiozawa, H. Hara, K. Yamazaki, K. Komori, N. Matsuhashi, T. Kato, Y. Kagawa, M. Yokota, E. Oki, S. Takahashi, T. Yoshino
Journal: Annals of Oncology (2022)
1711P Spatial transcriptomics reveals substantial heterogeneity in TNBC tumor and stroma compartments with potential clinical implications
Authors: X. Wang, D. Venet, F. Lifrange, D. Larsimont, M. Rediti, L. Stenbeck, D. Gacquer, F. Dupont, G. Rouas, M. Serra, J. Lundeberg, F. Rothé, C. Sotiriou
Journal: Annals of Oncology (2022)
1391P Tumor-first mutation-specific risk approach to trigger germline testing in castration-resistant prostate cancer
Authors: I.S.H. Kloots, M. Kets, J. Schuurs-Hoeijmakers, H. Westdorp, M. Coskunturk, H. Bloemendal, W.R. Gerritsen, I.M. van Oort, M. Ligtenberg, N. Mehra
Journal: Annals of Oncology (2022)
1710P Genomic landscape (GL) with potential of methylthioadenosine phosphorylase (MTAP) loss in clinically advanced breast cancer (CABC)
Authors: M. Bou Zerdan, P. Ashok Kumar, E.S. Sokol, D.C. Pavlick, M. Levy, N.A. Danziger, J.S. Ross, A. Sivapiragasam
Journal: Annals of Oncology (2022)
1723P CLEC3B mRNA expression levels are linked to distinct genetic backgrounds, transcriptomic signatures and survival in NSCLC
Authors: A. Seeber, Y. Baca, J. Xiu, S. Puri, T.K. Owonikoko, T. Oliver, K. Kerrigan, S. Patel, D. Uprety, H. Mamdani, A. Kulkarni, G. Lopes, B. Halmos, H. Borghaei, W. Akerley, S.V. Liu, W.M. Korn, A. Pircher, D. Wolf, F. Kocher
Journal: Annals of Oncology (2022)
1737MO Tumor and immune features associated with disease-free survival with adjuvant nivolumab in the phase III CheckMate 274 trial
Authors: A. Necchi, D.F. Bajorin, Y. Tomita, D. Ye, M. Agerbæk, D. Enting, A. Peer, M. Milowsky, K. Kobayashi, M-O. Grimm, F. Stenner-Liewen, J.M. David, J. Li, S.D. Chasalow, F. Nasroulah, A. Apfel, K. Unsal-Kacmaz, M.D. Galsky
Journal: Annals of Oncology (2022)
1500P Radiochemotherapy with gemcitabine as a radiosensitizer in patients with soft tissue sarcomas
Authors: L. Schneider, C. Albrecht, C. Grehn, T. Gryc, S. Knop, G. Siegler, A. Bott, M. Rottmann, M. Blos, U. Linnemann, J. Köhler, J. Jakob, P. Hohenberger, T. Papadopoulos, C. Meyer, V. Mordstein, None B. Stein, L. Gazdag, B. Reichert, M. Augustin
Journal: Annals of Oncology (2022)
1610P Humoral immune response to COVID-19 vaccination in patients with cancer: The ANRS0001S COV-POPART study
Authors: L.B. Luong Nguyen, M. Chalouni, P. Loubet, N. Dohollou, O. Tredan, M. Veyri, Z. Maakaroun-Vermesse, I. Ben Ghezala, E. Fourn, D. Merrien, C. Cracowski, A. Barquin, A. Levier, L. Wittkop, O. Launay, J-Y. Blay, J-P. Spano
Journal: Annals of Oncology (2022)
1473P A prognostic microRNA-based signature for relapse risk prediction and definition of therapeutic targets in patients with high-risk localized clear cell renal cell carcinoma
Authors: A. Pinto Marin, L. Trilla, J. Miranda, N.S. Vasudev, E. García, R. López-Vacas, N. Miranda, M. Wilson, E. López-Camacho, A. Pertejo-Fernández, M.I. Lumbreras Herrera, J. Brown, A. Zapater Moros, G.A. De Velasco Oria, D.E. Castellano Gauna, M.P. González-Peramato, E. Espinosa, R. Banks, J.Á. Fresno-Vara, A. Gámez
Journal: Annals of Oncology (2022)
1674P NT-I7 plus pembrolizumab combination treatment enhances infiltration of PD-1+ T cells and provides a more immunogenic tumor microenvironment: Biomarker data from the NIT-110 study
Authors: A. Naing, S. Ferrando-Martinez, A. Wolfarth, M. Xu, J.B. Goon, M.B. Ware, C. Haymaker, M.G. Raso, M. Chaney, U.I. Ezeanya, S. Dhar, H. Lee, T. Lee, T. Adebanjo, J. Fan, S.H. Yang, B.H. Lee, R. Kim
Journal: Annals of Oncology (2022)
1499P Phase I clinical &amp; immunologic data of SQ3370 in advanced solid tumors
Authors: S.P. Chawla, K. Batty, M. Alečković, V.A. Bhadri, N. Bui, A. Guminski, J.M. Mejía Oneto, S. Srinivasan, J. Strauss, V. Subbiah, M.C. Weiss, R. Wilson, N. Yee, M. Zakharian, V. Kwatra
Journal: Annals of Oncology (2022)
1447O Phase II study of belzutifan plus cabozantinib as first-line treatment of advanced renal cell carcinoma (RCC): Cohort 1 of LITESPARK-003
Authors: T.K. Choueiri, T. Bauer, J. Merchan, R. Figlin, A. Roy, R. Perini, D. Vickery, E. Arrowsmith
Journal: Annals of Oncology (2022)
1558MO Dissecting sexual health after breast cancer (BC) by longitudinal assessment of patient reported outcomes
Authors: M.A. Franzoi, M. Aupomerol, J. Havas, H. Hang, A. Di Meglio, M. Lambertini, C. Massarotti, C. Coutant, O. Tredan, F. Joly Lobbedez, P.H. Cottu, D. Soldato, M-A. Mouret, C. Tarpin, A. Arnaud, L. Fasse, S. Everhard, A-L. Martin, B. Pistilli, I.V. Luis
Journal: Annals of Oncology (2022)
1772P Characterisation of a DNA repair deficiency (DRD) biomarker phenotype in metastatic urothelial carcinoma (mUC) within the ATLANTIS clinical trial platform
Authors: S.J. Crabb, L. Dempsey, E. Soulis, S. Hinsley, Y.P. Song, J. Barber, J. Frew, J. Gale, G. Faust, S. Brock, U.B. McGovern, O.A. Parikh, D. Enting, S. Sundar, G. Ratnayake, K. Lees, S.A. Hussain, T.B. Powles, R. Jones, W. Tapper
Journal: Annals of Oncology (2022)
1553O Health-related quality of life (HRQoL) in the phase III TROPiCS-02 trial of sacituzumab govitecan (SG) vs chemotherapy in HR+/HER2- metastatic breast cancer (MBC)
Authors: H.S. Rugo, P. Schmid, S.M. Tolaney, F. Dalenc, F. Marmé, L. Shi, W. Verret, M. Gharaibeh, A. Bardia, J. Cortés
Journal: Annals of Oncology (2022)
1733MO First results from BladderPath: A randomised trial of MRI versus cystoscopic staging for newly diagnosed bladder cancer
Authors: N.D. James, S. Pirrie, W. Liu, K. Jefferson, J. Gallagher, A. Hughes, A. Knight, V. Nanton, H.P. Mintz, A. Pope, H. Doyle, J. Singh, S. Hafeez, P. Patel, J. Catto, R. Bryan
Journal: Annals of Oncology (2022)
1388P Interim safety analysis of nivolumab 3mg/kg and ipilimumab 1mg/kg (nivo3/ipi1) in molecular-selected patients (pts) with metastastic castration-resistant prostate cancer (mCRPC)
Authors: S. van Wilpe, H. Westdorp, I.S.H. Kloots, P. Slootbeek, M. den Brok, G. Adema, L. Kerkmeijer, R.J. Smeenk, M. Coskunturk, H. Bloemendal, J. Schalken, N.V. Erp, W.R. Gerritsen, N. Mehra
Journal: Annals of Oncology (2022)
1701P Consensus molecular subtypes in late-stage colorectal cancer
Authors: A. Bjerrum, T.O. Stannius, L. Belcaid, K.S. Rohrberg, I. Spanggaard, M. Hoejgaard, F.C. NIelsen, F.O. Bagger, C. Qvortrup
Journal: Annals of Oncology (2022)
1687P Targeted metabolomics reveals dynamic changes and potential therapeutic targets in the serum metabolome of patients receiving adoptive cell therapy with tumor infiltrating lymphocytes
Authors: L. Mantle, D. Millar, R. Laister, V. Sotov, L. Nguyen, C. Robert, M. Vilbert, T. Pimentel Muniz, I. Hirsch, M.F. Silva Almeida Ribeiro, E.C. Koch, P. Ohashi, M.O. Butler, S. Saibil
Journal: Annals of Oncology (2022)
1463P Patterns of care and outcomes of metastatic renal cell carcinoma (mRCC) patients (pts) with bone metastases (BM): A UK multicenter review
Authors: A. Challapalli, G. Ratnayake, J. McGrane, R. Frazer, S. Gupta, D.S. Parslow, S.J. Kingdon, A. Lydon, A. Sharma, M. Tuthill, C. McCusker, V. Ford, A. Ferrera, J.M. Malik, Z. Boh, E. Jones, None T.R. Geldart, S. Nelmes, J.E. Brown, A. Bahl
Journal: Annals of Oncology (2022)
1662MO Longitudinal analysis of circulating immune cell subsets in melanoma patients (pts) treated with neo-adjuvant ipilimumab (ipi) &amp; nivolumab (nivo)
Authors: R.C. Simpson, M. Batten, E.R. Shanahan, I. Pires da Silva, J.M. Versluis, I.L.M. Reijers, A.M. Menzies, R.P.M. Saw, M. Gonzalez, K.F. Shannon, A.J. Spillane, C.U. Blank, R.A. Scolyer, G.V. Long
Journal: Annals of Oncology (2022)
1381P A transcriptomic signature of AR activity prognosticates development of castration-resistance following metastasis-directed therapy in oligometastatic castration-sensitive prostate cancer
Authors: P.T. Tran, P. Sutera, M. Deek, K. Van der Eecken, A. Hakansson, S. Liu, J. Chang, V. Fonteyne, A. Mendes, N. Lumen, L. Delrue, S. Verbeke, K. De Man, D.Y. Song, C. Paller, E. Davicioni, S. Joniau, G. De Meerleer, T. Lotan, P. Ost
Journal: Annals of Oncology (2022)